دیگر

Redhill Pharma: Gut-Punch Lessons

Summary

Redhill Pharma’s latest secondary delivered an awful gut-punch to shareholders; there are lessons to be learned.

Lesson 1: it always takes more time to develop a great pharma pipeline into saleable, much less profitable, products.

Lesson 2: a corollary to lesson 1 is that it always takes more money to develop them.

Lesson 3: busy pipelines can signal potential cost pressures.

Observation: Redhill’s side business is still a work in progress.

Redhill Biopharma (RDHL) is a promising late clinical stage pharmaceutical company. Its recent distressing price action contains lessons that can help inform investment in many young pharma companies which have yet to realize sustainable product revenues. This posting will set out the lessons I have drawn while exploring Redhill’s urgent efforts to right its ship.

Redhill Pharma’s latest secondary delivered an awful gut-punch to shareholders; there are lessons to be learned.

On November 6, 2017, SA’s news feed ran the following headline:

RedHill prices ADS offering at $5.50; shares down 27% premarket

The impact of the news of this secondary was to immediately poleax Redhill’s stock price and things don’t seem to be correcting. The 1-year stock price chart below tells the story:

☑Refad more

عضویت در کانال زیست فن☑

Redhill Pharma: Gut-Punch Lessons

Rate this post
برچسب‌ها
نمایش بیشتر

نوشته‌های مشابه

دیدگاهتان را بنویسید

نشانی ایمیل شما منتشر نخواهد شد. بخش‌های موردنیاز علامت‌گذاری شده‌اند *

دکمه بازگشت به بالا
EnglishIran
بستن
بستن